Development and Validation of a Diabetes Risk Prediction Model With Individualized Preventive Intervention Effects
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf250 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Byron Jaeger und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology & Prevention, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Diabetes Association, NHLBI NIH HHS, NCATS NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Type 2 diabetes risk prediction models lack the option to predict risk conditional on initiating different preventive interventions. Our objective was to develop and validate a diabetes risk prediction model with individualized preventive intervention effects among racially diverse populations.
Methods
The derivation cohort included participants in the Diabetes Prevention Program (DPP) trial randomized to placebo, metformin, or intensive lifestyle intervention (n = 2640). A risk prediction model for incident diabetes was developed using Cox proportional hazards regression using clinically available predictors: sex, glycated hemoglobin, fasting plasma glucose (FPG), body mass index (BMI), triglycerides, and intervention. To create individualized intervention effects, pairwise interactions between intervention and age, FPG, and BMI were included. The discrimination, calibration, and net benefit of the model's 3-year predictions for incident diabetes were internally validated within the DPP and externally validated among participants with prediabetes in the Multi-Ethnic Study of Atherosclerosis (MESA; n = 2104).
Results
In DPP and MESA, mean (SD) age was 51 years (11) and 64 (10), and 67% and 50% of participants were women, respectively. The mean C-statistic was 0.71 [95% confidence interval (CI): 0.68, 0.74] in DPP and 0.86 (95% CI: 0.83, 0.88) in MESA. The optimal preventive intervention (lowest 3-year risk) was lifestyle for 86% and 97% of DPP and MESA participants, respectively, and metformin for the remaining. Model performance was similar across race/ethnicity groups.
Conclusion
This is the first study to develop and validate a diabetes risk prediction model with individualized preventive intervention effects that may improve clinical decision-making and diabetes prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology & Prevention, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
ORCID-Profile: Michael Patrick Bancks
Förderung
- American Diabetes Association
- NHLBI NIH HHS
- NCATS NIH HHS
- NIA NIH HHS
- Parke-Davis
- Bristol-Myers Squibb
- NIDDK NIH HHS
- National Institute of Child Health and Human Development
Zitieren
APA
Jaeger, B., Casanova, R., Demesie, Y., Stafford, J., Wells, B., & Bancks, M. P. (2025). Development and Validation of a Diabetes Risk Prediction Model With Individualized Preventive Intervention Effects. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf250
Vancouver
Jaeger B, Casanova R, Demesie Y, Stafford J, Wells B, Bancks MP. Development and Validation of a Diabetes Risk Prediction Model With Individualized Preventive Intervention Effects. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf250
BibTeX
@article{Jaeger2025,
author = {Jaeger, Byron and Casanova, Ramon and Demesie, Yitbarek and Stafford, Jeanette and Wells, Brian and Bancks, Michael Patrick},
title = {Development and Validation of a Diabetes Risk Prediction Model With Individualized Preventive Intervention Effects},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf250}
}
EUVIMED